MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer
L. Ellis, B. German, J. N. Singh, D. L. Burkhart, A. Sheahan, H. Bergom, K. L. Morel, H. Beltran, J. Hwang, K. Lawrenson
This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.
bioRxiv · Jan 31, 2024 · PreprintCancer Biology